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understanding the mechanisms underlying neural progenitor differentiation and neuronal 
fate specification is critical for the use of embryonic stem cells (EsCs) for regenerative 
medicine. Cortical interneurons are of particular interest for cell transplantation; however, 
only a limited subset of these neurons can be generated from EsCs. Here we uncover a pivotal 
role for Activin in regulating the differentiation and identity of telencephalic neural precursors 
derived from mouse and human EsCs. We show that Activin directly inhibits the mitogenic 
sonic hedgehog pathway in a Gli3-dependent manner while enhancing retinoic acid signalling, 
the pro-neurogenic pathway. In addition, we demonstrate that Activin provides telencephalic 
neural precursors with positional cues that specifically promote the acquisition of a calretinin 
interneuron fate by controlling the expression of genes that regulate cortical interneuron 
identity. This work demonstrates a novel means for regulating neuronal differentiation and 
specification of subtype identity. 
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During neurogenesis, the balance between signalling inputs that control neural progenitor self-renewal and differentia-tion is critical for the expansion of the stem cell pool or the 
initiation of the terminal differentiation programme. In the telen-
cephalon, the self-renewal of neural progenitors is thought to be 
under the tight control of a number of growth factors. For example, 
sonic hedgehog (Shh), as well as its patterning activities, promotes 
self-renewal and prevents differentiation within the telencephalon1. 
In contrast to this, retinoic acid (RA) acts as a pro-differentiation fac-
tor in a wide variety of neuronal settings2, and, in the telencephalon, 
inhibits progenitor proliferation and promotes neuronal differentia-
tion3. How these different growth factor inputs are coordinated to 
promote self-renewal or differentiation remains unknown.
A second key event during neurogenesis is the specification of 
neuronal subtype identity. The cerebral cortex functions in mem-
ory and higher-order cognitive processing. Two classes of neurons 
carry out these roles, the excitatory glutamatergic projection neu-
rons and the inhibitory GABAergic interneurons. Interneurons, 
comprising 20–30% of cortical neurons, modulate cortical output4 
and, during corticogenesis, regulate neural progenitor proliferation 
and migration5, as well as postnatal development of the cortical 
circuitry6. Most cortical interneurons can be subdivided into three 
main subtypes that express parvalbumin, somatostatin or calretinin, 
and mainly originate from distinct domains within the ventral tel-
encephalon and then migrate to the cortical region7. Somatostatin 
and parvalbumin-type interneurons are specified in the medial 
ganglionic eminence (MGE) by Shh-mediated induction of Nkx2.18. 
In contrast to this, calretinin interneurons form in the caudal 
ganglionic eminence (CGE)9, and the signals that control their 
specification have not been identified.
The ‘in vitro’ differentiation of embryonic stem cells provides 
a powerful tool to understand telencephalic development and is a 
potential source of cells for use in regenerative medicine. Special 
attention has been paid to cortical interneurons owing to their 
remarkable migratory capacity in postnatal cortex, their stere-
otypic differentiation after transplantation and their regulation of 
cortical activity10–13. The serum-free monolayer differentiation 
protocol allows to obtain in a reproducible manner relatively pure 
populations of telencephalic neural progenitor cells that respond to 
Shh signalling in the same way as occurs during normal develop-
ment14,15. Here, using embryonic stem cell (ESC)-derived neural 
precursors to identify novel morphogens that pattern the telen-
cephalon, we have found that Activin is a potent neurotrophic fac-
tor that induces differentiation into postmitotic neurons. We find 
that Activin does this in two ways, by promoting cell cycle exit via 
the inhibition of the Shh pathway and by enhancing RA signalling, a 
key pathway for neuronal terminal differentiation. Furthermore, we 
show that Activin signalling also confers positional identity to these 
neural precursors by directing them towards a CGE fate and there-
fore induces the formation of calretinin cortical interneurons.
Results
Activin induces neural precursor differentiation. Activin belongs 
to the TGFβ superfamily. During telencephalic development, Activin 
subunits, TGFβs and their receptors are widely expressed16 and high 
levels of Smad2/3 activation are observed in the lateral ganglionic 
eminence (LGE) and CGE17. However, very little is known about 
the roles of this signalling pathway in telencephalic development. 
To explore the role of Activin signalling, we differentiated mouse 
ESCs as a monolayer in serum-free media for 5 days15, the time 
point when the highest proportion of neural precursors are present, 
the expression of pluripotency markers is extinguished and there 
is a dramatic increase in the expression of ventral telencephalic 
markers (Supplementary Fig. S1). At this stage, cells were replated 
into poly-d-lysine- and laminin-coated dishes. This time point was 
considered as day 0 of our experiments.
Day 0 cultures were treated with 10 ng ml − 1 of Activin. After 
4 days, we observed that Activin-treated cells showed clear morpho-
logical signs of differentiation (Fig. 1a), reduced rosette formation, 
a dramatic decrease in the percentage of Nestin +  neural precursors 
and a comparable increase in the proportion of β-III-tubulin +  post-
mitotic neurons (Fig. 1a). Activin treatment did not alter the pro-
portion of AnnexinV +  or Caspase3 +  neural precursors or neurons, 
indicating that these changes were not due to a pro-survival role of 
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Figure 1 | Activin induces the differentiation of telencephalic neuronal precursors. (a) Control and Activin-treated cultures illustrating how Activin 
promotes neural precursor differentiation (arrowheads mark rosettes present in control cultures). The right panel contains a plot of the proportion of 
nestin +  cells/β-III-tubulin +  cells in these cultures: Activin treated 36 ± 5.5/62 ± 9.25% and control treated 62 ± 11.23/35 ± 6.46%. (b) Plot on the left 
shows the relative number of Annexin V + /PI − ve cells in control and Activin-treated cultures (these oscillate between 0.2–0.45% for Activin cultures and 
0.15–0.32% for control cultures). The panel on the right displays the Caspase3-positive neural precursors ands neurons in control and Activin-treated 
cultures. At day 3, 5.3 ± 0.3% of cells in Activin-treated cultures and 4.7 ± 0.3% in control cultures were double Caspase3/β-III-tubulin +  and 1.8 ± 0.1%  
in Activin cultures and 2.6 ± 0.2% in control cultures were double Caspase3/nestin +  cells. (c) Immunofluorescent analysis and quantification of  
nestin + /Brdu +  cells in control (69 ± 5.2%) and Activin (48 ± 3.84%) cultures after 3 days of treatment showing how Activin-treated precursors 
proliferate slowly. (d) sorted sox1 +  cells differentiate in response to Activin (nestin + /β-III-tubulin +  cells: Activin cultures 8.69 ± 1.65/91.3 ± 17% and 
control cultures 61.27 ± 6.32/38.7 ± 4.64%). For all experiments, n = 3, mean ± s.e.m. student’s t-test. *P < 0.001. EsCs were differentiated for 5 days as a 
monolayer, then replated into poly-d-lysine/laminin-coated dishes and cultured in nBB27 media (controls) or nBB27 + 10 ng ml − 1 Activin. For (d), sox +  
cells were sorted at day 5 of monolayer differentiation and replated as above. scale bar = 50 µm (a and c) and 25 µm (d).
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Activin (Fig. 1b). Interestingly, TGFβ1 and TGFβ3 did not affect 
the proportions of neural precursors and neurons of our cultures 
(Supplementary Fig. S2), indicating that our observations are 
specific to the Activin members of the TGFβ family. Together, 
these findings suggested that Activin induces differentiation of 
telencephalic progenitors into postmitotic neurons.
To test how Activin affects the cell cycle of neuronal precursors, 
we measured the percentage of Nestin +  cells that incorporate BrdU 
after a pulse of 6 h. When compared with controls, Activin-treated 
cells showed a significantly lower proportion of neuronal precursors 
incorporating BrdU (Fig. 1c), suggesting that Activin treatment was 
causing a decrease in the number of neural progenitors re-entering 
the cell cycle and therefore initiating the differentiation process.
The observation that Activin induces differentiation of cultures 
predominately composed of neural precursor cells (Supplementary 
Fig. S1a) suggests that it is directly acting on this cell type. To con-
firm this finding, Sox1–green fluorescent protein (GFP) cells15 were 
sorted for GFP expression and treated with Activin for 4 days. When 
this was done, we observed that Activin dramatically decreased the 
proportion of Nestin +  neural precursors and increased the propor-
tion of β-III-tubulin neurons (Fig. 1d). Therefore, we conclude that 
Activin induces the differentiation of Sox1-expressing telencephalic 
neural precursor cells into postmitotic neurons.
Activin-generated neurons are electrophysiologically active. We 
next investigated the electrophysiological properties of Activin-
treated and control cells at day 5 in vitro. Cells were visually identi-
fied as neurons and targeted for whole-cell current-clamp recordings 
(Fig. 2a). We observed no differences in resting membrane potential, 
input resistance or whole-cell capacitance between Activin-treated 
and control cells ( − 30.4 ± 14.8 versus  − 38.9 ± 14.7 mV; 1.9 ± 1.6 
versus 1.5 ± 1.3 GΩ; 6.5 ± 3.6 versus 6.3 ± 2.1 pF (Activin versus con-
trol, mean ± s.d.); P>0.05, t-tests). To examine their ability to fire 
action potentials (APs), cells were injected with depolarizing current 
pulses from their resting membrane potential. We found that cells 
could be distinguished into four functional subgroups, which pre-
sumably reflect different stages in their maturation (Fig. 2b). Type 1 
cells did not exhibit any voltage-sensitive conductances. Other 
cells exhibited progressive stages of maturation, from a single broad 
AP (Type 2), to a full overshooting AP (Type 3), to multiple APs 
(Type 4). We found that Activin-treated cells could fire APs, 
and that these neurons fell mainly into Type 2–4 neuronal types 
(Fig. 2c). These results indicate that Activin-treated telencephalic 
neural precursors can develop into functionally mature neurons.
The Shh pathway is inhibited by Activin. Shh has been widely 
described as a mitogenic factor for neuronal precursors, both in vivo 
and in vitro1, and is required to maintain stem cell-derived neural 
precursors during rosette growth18. We therefore analysed if Shh 
signalling has a similar role in telencephalic neural precursors. We 
found that treatment of these cells with Shh increased the propor-
tion of neural precursors and decreased the proportion of neurons 
(Fig. 3a). In contrast to this, treatment with cyclopamine (a specific 
Shh pathway inhibitor) lead to the opposite effect (Fig. 3a). To test 
if Shh signalling was affecting the proliferation of neural precursors, 
analysis of double BrdU + /Nestin +  cells was done after a 6-h BrdU 
pulse. We found that in the presence of exogenous Shh, there was a 
significant increase in the proportion of double-positive cells and 
Shh inhibition with cyclopamine led to a dramatic decrease in the 
number of neuronal precursors that incorporated BrdU (Fig. 3a). 
These results indicate that Shh is mitogenic to telencephalic neural 
precursors.
To investigate the mechanism of how Activin promotes telen-
cephalic neuronal precursor differentiation, we analysed if Shh sig-
nalling was affected in Activin-treated neural precursors. Gli1 and 
Ptch1 are two targets of the Shh signalling pathway1. The expres-
sion of both these genes is high in control cultures at day 2, cor-
relating with the rapid proliferation of the cells at this stage, and 
then decreases as terminal differentiation increases in these cultures 
(Fig. 3b). In contrast to this, Activin-treated cells show very low 
levels of expression of these genes throughout the whole-culture 
period (Fig. 3b,c), suggesting that Activin is inhibiting their expres-
sion. Cyclin D1 has also been shown to be a target of Shh signal-
ling in neural precursor cells19. We observed the levels of Cyclin D1 
protein expression to be high in control cells throughout the culture 
period. However, in Activin-treated cells Cyclin D1 protein levels 
were dramatically reduced (Fig. 3c), further supporting the concept 
that Activin is inhibiting Shh signalling.
To further test the ability of Activin to repress the Shh pathway, 
day 2 control cultures were treated with Activin, Shh, cyclopamine 
or with Shh plus Activin for 24 h. We observed that the expression 
of Gli1 and Ptch1 was significantly reduced by Activin under these 
conditions, and that this reduction was comparable to that achieved 
by cyclopamine treatment (Fig. 3d). Therefore, our results suggest 
that in telencephalic neural precursors Activin is initiating differen-
tiation by directly blocking the mitogenic effects of Shh signalling.
Inhibition of Shh signalling by Activin requires Gli3. Gli3 is the 
main repressor of the Shh pathway during telencephalic develop-
ment8. The Activin signal transducer Smad2 can bind to Gli3R 
and inhibit its activity; however, upon TGFβ stimulation this 
interaction is interrupted and Gli3R is released to inhibit Shh 
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Figure 2 | Electrophysiological activity of Activin-generated neurons.  
(a) Representative differential interference contrast images of whole-cell 
recordings of control and Activin-treated neurons. (b) Representative 
examples of the four different types of responses of neurons to depolarizing 
pulses. (c) Activin-treated cells preferentially show an  
ability to fire APs (82%; n = 23), compared with controls (52%; n = 21). 
EsCs were differentiated for 5 days as a monolayer, then replated into poly-
d-lysine/laminin-coated dishes and cultured in nBB27 media (controls) or 
nBB27 + 10 ng ml − 1 Activin. scale bar = 10 µm.
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signalling20. This raises the possibility that Activin may inhibit the 
Shh pathway via Gli3.
To test this, we used ESCs that carry a null mutation in Gli321. 
Gli3 − / −  neuronal cultures showed enhanced proliferation and dis-
played an increase in Nestin-expressing neural precursors when 
compared with wild-type cells (Supplementary Fig. S3a,b). We 
found that in contrast to what occurs with wild-type cells, Activin 
was unable to induce differentiation in Gli3 − / −  neural precursor 
cultures (Supplementary Fig. S3a,b). The low efficiency of neuronal 
differentiation observed in Gli3 − / −  cells even after Activin treat-
ment is likely to be due to a hyperactivation of the Shh pathway as 
we observe an upregulation of the transcription of the Shh targets 
Gli1, Ptch1 and Nkx2.1 in Gli3 − / −  cells that is unaffected by Activin 
treatment (Supplementary Fig. S3c,d). Together, these results indi-
cate that Activin requires Gli3 to inhibit the Shh pathway.
To further address the interaction between Activin and the Shh 
pathway, we blocked Shh signalling in Gli3 − / −  neuronal cultures 
using cyclopamine. Interestingly, we found that while cyclopamine 
increased differentiation in these cells, it induced a significantly 
lower proportion of neurons than Activin did in control cells 
(Fig. 4a versus Fig. 1a). Therefore, Activin must have other pro- 
differentiation roles in addition to suppressing Shh signalling. 
In support of this, the combination of cyclopamine and Activin 
treatment led to differentiation levels of Gli3 − / −  neural precur-
sors that were similar to those observed in Activin-treated control 
cells (Fig. 4a versus Fig. 1a). This indicates three inferences: (1) that 
Activin needs to suppress Shh signalling to induce differentiation; 
(2) that Activin inhibits Shh signalling via Gli3; and (3) that, in 
addition to inhibiting the Shh pathway, Activin must be performing 
other roles.
To confirm this third hypothesis, we directly compared the effects 
of Activin and Shh inhibition on telencephalic neural precursor 
cells. When Sox1–GFP cells were sorted and treated with Activin or 
cyclopamine, we observed that while cyclopamine produced only a 
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Figure 3 | Activin antagonizes the mitogenic effects of Shh. (a) Immunostaining (left panels) and quantifications (right panel) indicating that shh  
promotes and cyclopamine inhibits proliferation in neural precursors (nestin + /β-III-tubulin +  cells in cyclopamine 49 ± 4.3/35.1 ± 1.8%, shh 80.3 ± 3.2/ 
14.8 ± 0.7% and control cultures 68.4 ± 7.2/20.1 ± 2.8%; n = 3, mean ± s.e.m.). (b) Relative expression levels of Gli1 and Ptch1 during the first 5 days of 
Activin or control treatment. (c) Immunoblot analysis of Gli1 and Cyclin D1 levels during the first 4 days of Activin or control treatment illustrating how 
Activin represses the expression of these proteins. (d) normalized mRnA levels of Gli1 and Ptch1 after 24 h exposure to the indicated conditions illustrating 
how shh induces the expression of these genes and Activin inhibits their expression (n = 3, mean ± s.e.m. student’s t-test. *P < 0.005 and **P < 0.05). 
EsCs were differentiated for 5 days as a monolayer, then replated into poly-d-lysine/laminin-coated dishes and cultured in nBB27 media (controls), 
nBB27 + 10 ng ml − 1 Activin, nBB27 + 100 ng ml − 1 shh, nBB27 + 10 µm cyclopamine or nBB27 + 10 ng ml − 1 Activin + 100 ng ml − 1 shh. scale bar = 50 µm.
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relatively minor change in the proportion of neural precursors and 
neurons in the cultures, Activin induced high levels of differentia-
tion (Fig. 4b). Therefore, inhibition of Shh alone could not explain 
the full range of differentiation effects displayed by Activin.
Activin enhances the response to RA signalling. RA is essential for 
telencephalic development and acts as a pro-differentiation factor 
in a wide variety of neuronal settings2. Conversion of retinaldehyde 
to RA is regulated by the Aldh1a subfamily of proteins, and dur-
ing telencephalic specification the transcription of these factors 
is controlled by the Activin signal transducer Foxh122. Therefore, 
we tested if the regulation of RA signalling could be an additional 
mechanism that explains Activin’s pro-differentiation effect.
We first analysed the efficiency with which Activin could induce 
the differentiation of neural precursors in the absence of exogenous 
vitamin A (VitA), the RA precursor. For this, we carried out neural 
differentiation assays using VitA/retinol-deficient B27. We found 
that while Activin could efficiently induce differentiation when 
assays were carried out in the presence of VitA, it was unable to 
induce differentiation in its absence (Fig. 5a). In contrast, the dif-
ferentiation induced by inhibiting Shh signalling with cyclopamine 
was not significantly affected by the absence of exogenous VitA 
(Fig. 5a). To test which receptors were mediating the RA response, 
we inhibited RAR and RXR signalling with small-molecule antago-
nists. When this was done, we observed that while inhibition of the 
RAR receptors significantly reduced the amount of differentiation 
induced by Activin, blocking the RXR receptors did not (Fig. 5b). 
Together, these data argue that enhancing RA signalling is one way 
by which Activin induces differentiation and that this role must be 
independent of the inhibition of Shh signalling.
We next analysed how Activin modulates RA signalling and for 
this we asked if it was regulating the expression of components of 
the RA pathway. We observed that Activin increased the expression 
of the Foxh1 targets Aldh1a1-3 (Fig. 5c) and inhibited the expres-
sion of the RA degrading enzyme Cyp26b1 in neural precursors cul-
tured in the absence of VitA (Fig. 5b). In contrast to this, Activin did 
not affect the expression of the RA responsive gene Stra6 (Fig. 5b), 
indicating that although Activin was controlling the expression of 
key components of the RA pathway, it was not regulating the expres-
sion of genes downstream of RA signalling.
To test the physiological importance of this regulation, we 
asked if the increase in expression of RA pathway components by 
Activin enhanced the potential of telencephalic neural precursors to 
respond to RA. For this, we cultured these precursors in the absence 
of VitA, with or without Activin for 4 days, then treated the cells 
with VitA for 24 h and analysed Stra6 expression. We observed that 
cells that had been pre-treated with Activin showed 7 times higher 
Stra6 expression compared with untreated cells (Fig. 5b), indicating 
that Activin sensitizes telencephalic neural precursors to RA signal-
ling by increasing the ability of these cells to metabolize VitA and 
decreasing the degradation of RA.
Our data suggest that the neurogenic effects of Activin are due 
to the coordinated inhibition of the Shh pathway and the enhance-
ment of the RA response. For this reason, telencephalic neuronal 
precursors were treated with cyclopamine and with increased con-
centrations of RA to see if this would mimic the effects of Activin. 
We observed that although RA did not induce differentiation, the 
combination of cyclopamine and 10 µm RA significantly increased 
the differentiation of neuronal precursors when compared with 
cyclopamine-treated cells (Supplementary Fig. S4). This synergistic 
effect suggests that the pro-differentiation role of Activin is mainly 
due to a repression of Shh pathway and to an enhancement of the 
response to RA signalling.
Induction of CGE identity by Activin. To establish if Activin 
confers positional identity to telencephalic neuronal precursors, 
we analysed the expression of characteristic patterning markers 
of the telencephalon. At 12.5 d.p.c., roughly the equivalent stage 
of the endpoint of our neuronal differentiation assays, the telen-
cephalon is divided into the cortical plate, found dorsally, and the 
ganglionic eminences, located ventrally. The ganglionic eminences 
are in turn subdivided into the MGE found in a ventral location, 
the LGE and the CGE. These regions can also be distinguished 
molecularly, with Pax6 being expressed in the pallium, Nkx2.1 in 
the MGE and Gsx2 showing higher levels of expression in the LGE 
and CGE.
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treated 8.7 ± 1.7/91.3 ± 1.7%). For all experiments n = 3, average ± s.e.m.; student’s t-test compared with control treatment. *P < 0.005 and **P < 0.05. 
EsCs were differentiated for 5 days as a monolayer, then replated into poly-d-lysine/laminin-coated dishes and cultured in nBB27 media (controls), 
nBB27 + 10 ng ml − 1 Activin, nBB27 + 10 µm cyclopamine or nBB27 + 10 µm cyclopamine + 10 ng ml − 1 Activin. For (b), sox +  cells were sorted at day 5 of 
monolayer differentiation and replated as above. scale bar = 25 µm.
ARTICLE

nATuRE CommunICATIons | DoI: 10.1038/ncomms1817
nATuRE CommunICATIons | 3:841 | DoI: 10.1038/ncomms1817 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
Specification of the MGE requires Shh signaling, and Nkx2.1 has 
been shown to be a Shh target23–25. In agreement with the role of 
Activin in suppressing Shh signalling, we found that Activin caused 
a fivefold repression in Nkx2.1 expression in telencephalic neuro-
nal cultures, an inhibition similar to that seen with cyclopamine 
treatment (Fig. 6a). A similar downregulation was observed in 
the expression of Lhx6, a marker of postmitotic migrating MGE-
derived neurons26,27, after Activin treatment (Fig. 6a), indicating 
that unlike control cultures, Activin treatment was not leading to 
the acquisition of an MGE fate. We next examined the expression 
of Pax6, whose expression is promoted by cyclopamine and sup-
pressed by Shh in ESC-derived telencephalic neural cultures14,28, 
and found that Activin had little effect on its expression (Fig. 6a). In 
contrast to this and unlike what occurs in control cultures, or after 
Shh or cyclopamine treatment, we observed that Activin caused 
a 13-fold increase in the mRNA expression of Gsx2 and a 7-fold 
increase in the proportion of Gsx2-expressing cells (Fig. 6a–b). This 
suggests that Activin is inducing telencephalic precursors to adopt 
an LGE/CGE fate.
The most ventral part of the LGE is characterized by low 
expression of Gsx2 and the absence of Er81 expression and later 
by increased Islet1 expression. The most dorsal part of the LGE 
expresses Gsx2 and Er81. The CGE has been recently described as 
a prolongation of the LGE region and of part of the MGE9,29,30. We 
observed that Activin-treated cells did not show any increase in 
Islet1 expression (data not shown), but did show a fivefold increase 
in Er81 expression compared with controls (Fig. 6c), suggesting a 
dorsal LGE or CGE fate. To better discriminate between LGE and 
CGE, we analysed the expression of genes that has been previously 
found enriched in CGE when compared with LGE31–33. We found 
the expression of Lhx2, Zcchc12 and Crabp1 also to be upregulated 
in Activin-treated cells (Fig. 6c), and that the proportion of neural 
progenitors and neurons expressing CoupTFII (a gene expressed 
preferentially in the CGE9,32) increased upon Activin treatment 
(Supplementary Fig. S5a), supporting that the telencephalic pro-
genitors in these cultures were acquiring a CGE identity.
The CGE produces calretinin-positive GABAergic interneurons 
that will migrate to the cortex27,29,34–36. The homeobox genes Dlx2, 
Dlx5 and Dlx6 are expressed in all developing and mature corti-
cal interneurons throughout the subpallial domain as well as in a 
number of other non-cortical neuronal cell types37,38. We observed 
that Activin treatment increased the levels of expression of all 
these genes (Fig. 6d) and 52 ± 5% of Activin-treated cells were Dlx2 
expressing (Supplementary Fig. S5b). Activin treatment also resulted 
in a fivefold increase in the proportion of GABA + /β-III-tubulin +  
neurons (Fig. 6e) and a dramatic enrichment in calretinin + /β- 
III-tubulin +  cells (Fig. 6f). To enhance the maturation of these 
interneurons, Brain Derived Neurotrophic Factor (BDNF) was 
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Figure 5 | Activin enhances RA signalling. (a) Analysis of nestin and β-III-tubulin immunostaining after 4 days of treatment with control conditions,  
Activin or cyclopamine in the presence or absence of exogenous RA (VitA). Charts on the right show the quantification for each treatment and illustrate 
that while cyclopamine can induce differentiation in the absence of exogenous VitA, Activin cannot (nestin + /β-III-tubulin +  cells,  + VitA: control 63 ± 3.7/ 
36 ± 4.2%; Activin 39 ± 3.5/60 ± 8%; cyclopamine 51.8 ± 4.43/48.12 ± 4% treated cells. minus VitA: control 67 ± 5.2/31 ± 2%; Activin 66.4 ± 4.8/33 ± 7%; 
and cyclopamine-treated cells 57.5 ± 4.1/42 ± 4.8%). (b) Quantification of the proportion of neural precursors and neurons indicates that inhibition of  
RAR but not RXR blocks the neural differentiation induced by Activin. nestin + /β-III-tubulin +  cells:  + VitA = 67 ± 4.69/26 ± 2.34%;  − VitA = 68 ± 5.73/28 ±  
1.39%;  − VitA + Actv = 62 ± 6.71/33 ± 2.2%;  + VitA + Actv = 28 ± 2.54/63 ± 3.9%;  + VitA + Actv + RAR inhibitor = 51 ± 3.57/45 ± 3.51% (**P < 0.005 for 
the comparison between  + VitA + Act and  + VitA + Act + RAR inhibitor);  + VitA + Actv + RXR inhibitor = 34 ± 3.43/61 ± 6.21%. (c) Quantitative reverse 
transcriptase PCR analysis indicating how the expression of the Aldh1 family of genes are promoted by Activin signalling while Cyp26b1 is repressed. The 
RA target gene Stra6 is only upregulated by Activin in the presence of VitA, suggesting that Activin enhances the response to RA rather than increases RA 
signalling per se. (c) n = 3, average ± s.e.m. student’s t-test compared with control treatment. *P < 0.05 and **P < 0.005. For (a,b), EsCs were differentiated 
for 5 days as a monolayer, then replated into poly-d-lysine/laminin-coated dishes and cultured in nBB27 media (controls), nBB27 + 10 ng ml − 1 
Activin, nBB27 + 10 µm cyclopamine, nBB27 + 10 µm RXR inhibitor, nBB27 + 10 µm RXR inhibitor + 10 ng ml − 1 Activin, nBB27 + 10 µm RAR inhibitor or 
nBB27 + 10 µm RAR inhibitor + 10 ng ml − 1 Activin. The nBB27 media were either VitA deficient or supplemented with VitA for these experiments.  
For (c), EsCs were differentiated for 7 days as a monolayer in nBn2 and B27 minus VitA, then replated into poly-d-lysine/laminin-coated dishes and 
cultured for 4 days in nBB27 (VitA deficient) media (controls), or nBB27 (VitA deficient) + 10 ng ml − 1 Activin. sTRA6 expression was  
analysed in these samples after being switched to nBB27 ( + VitA) media and cultured for a further 24 h. scale bar = 50 µm. Inhb., inhibition.
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added from day 7 to 12 of differentiation. This led to 76.34 ± 6.8% of 
calretinin-expressing neurons also expressing GABA (Supplemen-
tary Fig. S5c) and 67.6 ± 6.5% expressing GAD67 (data not shown). 
In contrast to this, we observed that only 0.001% of Activin-treated 
neurons expressed other interneuron markers, such as somato-
statin (data not shown). Of the calretinin-positive neurons,  < 5% 
expressed tyrosine hydroxylase, ruling out they could be olfactory 
bulb interneurons of the glomerular layer (Supplementary Fig. S5c 
and S5c’), and 95.7 ± 5% of them expressed the CGE marker COUP-
TFII (Supplementary Fig. S5d). Interestingly, we also observed that 
Activin treatment led to an enrichment in the proportion of Reelin-
expressing cells, another type of interneurons derived from the CGE 
(control: 6 ± 0.5% and in Activin-treated cells: 14.38% ± 1.2; Supple-
mentary Fig. S5e,f). The observation that only a small proportion of 
calretinin-positive neurons also expressed Reelin (16 ± 1.44%; Sup-
plementary Fig. S5e,f) indicates that these cells are not Cajal Retzious 
neurons. Together, these observations strongly suggest that Activin 
is promoting CGE identity and the formation of cortical calretinin 
interneurons derived from this subregion of the forebrain.
To address if the neurons we generate by Activin treatment can 
survive and integrate in vivo, we injected these neurons into the 
somatosensory cortex of adult mice. We observed that telencephalic 
neural precursors derived from Activin-treated, GFP-labelled ESCs 
could be observed 1 month after transplantation, predominantly 
adjacent to the site of injection (Supplementary Fig. S6a). Interest-
ingly, those cells that were found away from the site of injection 
expressed calretinin, were vertically oriented and bipolar (Supple-
mentary Fig. S6b), supporting our conclusions that they are likely 
calretinin interneurons. Remarkably, these neurons formed both 
dendrites and dendritic spines, suggesting that they are mature and 
physiologically active neurons (Supplementary Fig. S6c). Together, 
these data suggest that the calretinin neurons generated by Activin 
treatment of ESC-derived telencephalic neuronal precursors are 
able to integrate in vivo and are physiologically active.
A conserved role for Activin in human pluripotent stem cells. 
To determine if the roles of Activin in inducing neuronal precur-
sor differentiation, providing a CGE fate and calretinin interneuron 
identity are conserved in humans, we analysed the effect that Activin 
treatment has on telencephalic neural precursors derived from two 
independent lines of human ESCs (H1 and H7) or two independ-
ent lines of human-induced pluripotent stem cells (iPSCs) (2F8 and 
4FHuang). Human embryonic stem cells (hESCs) were differenti-
ated along a neural lineage as previously described39. Using this pro-
tocol, in H7 cells at day 17, the expression of pluripotency markers 
is extinguished and the majority of the cells become telencephalic 
neural precursors expressing SOX1 and PAX6 (Supplementary 
Fig. S7a,c). At day 19, cells were replated on poly-d-lysine- and 
laminin-coated dishes and treated with Activin for 6 days. In H1 
and the IPSCs, differentiation occurred more rapidly and therefore 
Activin was added at day 9 for 6 days (Supplementary Fig. S7a).
We first analysed the pro-differentiation capacity of Activin in 
H7 hESCs and found that similar to what occurred in mouse ESCs, 
Activin treatment reduced the proportion of Nestin-positive neural 
precursors and increased the proportion of β-III-tubulin neurons 
(Fig. 7a,b). Similar results were obtained with the H1 and IPSC lines 
(data not shown). This indicated that Activin also induces neuro-
nal differentiation of human pluripotent stem cells. We next tested 
if Activin could inhibit the targets of Shh signalling as well as if it 
is required for RA signalling during the differentiation of neural 
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Figure 6 | Activin provides telencephalic neuronal precursors with a CGE identity. (a) Quantitative reverse transcriptase PCR analysis of telencephalic 
gene expression indicates that Activin promotes Gsx2 and inhibits Nkx2.1 and Lhx6 expression. (b) Immunofluorescent analysis (left panel) and 
quantification (right panel) of Gsx2 +  cells indicates that Activin induces this cell type (control 2.8 ± 0.3% and Activin treated 21 ± 1.9%). (c) normalized 
mRnA levels of CGE genes and (d) Dlx gene expression indicating that Activin induces the expression of these genes. (e) Immunofluorescent images (left 
panels) and quantification (right panel) of β-III-tubulin/GABA double-positive cells (control day 6: 5.84 ± 0.5%; control day 8: 12.51 ± 1.18%; Activin day 
6: 31.29 ± 1.18%; Activin day 8: 58.93 ±  − 7.2%) and (f) β-III-tubulin/calretinin double-positive cells (control day 6: 3.3 ± 0.12%; control day 8: 4.2 ± 0.4%; 
Activin day 6: 25 ± 6.2%; Activin day 8: 38.72 ± 4.3%) illustrating how Activin promotes the development of GABAergic calretinin-positive interneurons. 
For all experiments n = 3, mean ± s.e.m. EsCs were differentiated for 5 days as a monolayer, then replated into poly-d-lysine/laminin-coated dishes and 
cultured in nBB27 media (controls) or nBB27 + 10 ng ml − 1 Activin for 3 days (a), 2 days (b), 4 days (c,d) or 6–8 days (e,f). BDnF (10 ng ml − 1) was added 
from day 7 after re-plating. scale bar = 50 µm.
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precursors derived from human ESCs. We found that, while a 6-day 
Activin treatment resulted in a moderate inhibition of the Shh tar-
gets PTCH1 and GLI1 in hESC-derived neural progenitors, Activin 
clearly suppressed PTCH1 and GLI1 induction by exogenous Shh 
(Supplementary Fig. S8a). In these cells, we also observed an upreg-
ulation of Aldh1a1 and a repression of Cyp26b1 (Supplementary 
Fig. S8b), suggesting that RA signalling was enhanced. To further 
test if RA signalling is required for Activin to induce neuronal dif-
ferentiation in neural precursors derived from hESCs, we either per-
formed the differentiations in the absence of exogenous RA, in the 
presence of an RAR inhibitor or in the presence of an RXR inhibi-
tor. We observed that as with mouse ESCs, the ability of Activin to 
induce differentiation was compromised in the absence of RA or by 
inhibition of the RAR receptors, but that blocking the RXR recep-
tors had little effect on the ability of Activin to induce differentia-
tion (Supplementary Fig. S8c,d). Interestingly, we observed that the 
combination of both RAR and RXR inhibitors led to the death of 
the telencephalic neural precursors derived from mESCs and hESCs 
(data not shown). This contrasts with what is seen with precursors 
of the spinal cord derived from hESCs40, suggesting that neural 
precursors with different regional identity are differentially sensi-
tive to the pan-inhibition of RA receptor signalling. In conclusion, 
we observe that both in mESCs and hESCs Activin requires RA 
signalling via the RAR receptors to promote differentiation.
When we analysed how Activin affected the patterning of 
neural precursors derived from hESCs, we found that it induced a 
sixfold increase in Dlx2 mRNA levels, a sevenfold stimulation of 
Gsx2 expression, a ninefold increase in the levels of GAD67 and a 
fourfold increase in calretinin expression (Fig. 7c). Double staining 
for β-III-tubulin/calretinin indicated that 74.5 ± 4.2% of postmitotic 
neurons were calretinin positive, a tenfold enrichment with respect 
to controls (Fig. 7d,e). Furthermore, the vast majority of these cal-
retinin neurons expressed GABA (94.73 ± 2.07%; Fig. 7e). These 
results suggest that, as occurs with mouse cells, Activin can induce 
a CGE fate and cortical calretinin interneuron identity in neural 
precursors derived from hESCs. We also observed that Activin had 
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Figure 7 | The roles of Activin are conserved in hESCs. (a) Immunostaining and (b) quantification indicating that Activin induces the differentiation of neural 
precursors derived from human EsCs (nestin + /β-III-tubulin +  cells: control 60 ± 7/13 ± 1.6% and Activin-treated cells 38 ± 8/35 ± 7.7%). (c) Quantitative 
reverse transcriptase PCR analysis of the expression of GSX2, DLX2, GAD67 and CALB2 indicating that Activin promotes the expression of these genes.  
(d) Immunostaining and (e) quantification of β-III-tubulin/calretinin double-positive cells indicating that Activin promotes the formation of calretinin 
interneurons from neural precursors derived from human EsCs (control 7.18 ± 0.35%; Activin-treated cells 74.5 ± 4.2%). For all experiments n = 3, mean ±  
s.e.m. student’s t-test compared with control treatment. *P < 0.05 and **P < 0.005. hEsCs were differentiated in n2B27 with 100 ng ml − 1 noggin, 10 µm 
sB431542 and 200 nm dorsomorphin for 4 days (H1/IPsCs) or for 5 days (H7), then cultured in n2B27 with 100 ng ml − 1 noggin and 200 nm dorsomorphin 
for 3 days (H1/IPsCs) or 4 days (H7) and after a further 2 days, culture in n2B27 alone cells were passaged. At this stage, cells were replated into fibronectin-
coated dishes and cultured in n2B27 for a further 2 days (H1/IPsCs) or 10 days (H7) and split again. Cells were then replated into poly-l-lysine/laminin-
coated dishes and cultured in n2B27 (controls) or n2B27 + 10 ng ml − 1 Activin for 6 days (H1/iPsCs) or 7 days (H7). scale bar = 25 µm (a) and 50 µm (d).
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similar roles during the neuronal differentiation of human-iPSCs 
(Supplementary Fig. S7d). Therefore, the roles of Activin in ESC-
derived, forebrain-like neural precursors appears to be conserved 
between the mouse and humans.
Discussion
Cell replacement therapy using ESCs holds great promise for the 
treatment of many central nervous system diseases and injuries that 
to date have little or no therapy available, including traumatic injury, 
neurodegenerative diseases and stroke. ESCs also provide invalua-
ble tools for drug discovery and for furthering our understanding of 
the development of the nervous system in health and disease. In this 
paper, using telencephalic neural precursors derived from mouse 
and human ESCs, we show that Activin controls two key aspects 
of neurogenesis, the decision of neural precursors to self-renew or 
differentiate, and their choice of neuronal subtype identity.
Differentiation of neuronal precursors into postmitotic neurons 
requires the careful coordination of signals that inhibit self-renewal 
with those that implement the programme of terminal differen-
tiation. The self-renewal of neural precursors is controlled by Shh 
signalling both in vivo and in vitro1. ESC-derived neural precur-
sors display endogenous Shh activity14 and this activity is required 
to maintain stem cell-derived neural precursors during rosette 
growth18. In this work, we show that the crosstalk between Shh 
and Activin signalling controls the balance between self-renewal 
and differentiation of telencephalic neural precursors derived from 
ESCs. We find that in these cells Shh is a potent mitogenic factor and 
that Activin induces differentiation by inhibiting Shh signalling in a 
Gli3-dependent manner and in this way initiates the differentiation 
process (Fig. 8).
The second way by which Activin induces differentiation is by 
enhancing the response of telencephalic neural precursors to RA, 
the pathway that implements neurogenic differentiation2 (Fig. 8). 
We find that Activin treatment leads to an increase in the expres-
sion of genes that promote RA signalling, such as Aldh1a1-3, that 
have already been shown to be direct targets of Activin signalling in 
the forebrain22, and to a repression of those that inhibit it, such as 
Cyp26b1. We suggest that these changes result in a sensitization of 
the telencephalic neural precursors to VitA, so that when these cells 
are presented with VitA they can rapidly undergo differentiation. By 
inhibiting the pathway that controls self-renewal and enhancing the 
response to the pro-neurogenic pathway, Activin ensures that the 
whole differentiation process of telencephalic neural progenitors is 
tightly regulated. The fact that in neural precursors derived from 
hESCs (our work) and in the chick spinal cord41,42 Activin also 
promotes differentiation suggests that this role may be conserved 
in a wide variety of neuronal settings. Interestingly, in the chick 
neural tube the Activin effector Smad3 induces differentiation by 
activating p27kip1 expression42. However, we observed no change in 
p27kip1 expression upon Activin treatment of telencephalic neural 
precursors derived from ESCs (data not shown), suggesting that the 
downstream molecular response to Activin signalling varies with 
the cellular context.
In addition to inducing differentiation, we find that Activin pro-
vides neural progenitors with neuronal subtype identity (Fig. 8). 
We show that in telencephalic neural precursors derived both from 
mouse and human ESCs, Activin regulates the two transcription 
factors that control interneuron progenitor fate to an LGE/CGE or 
MGE identity. Activin specifically promotes Gsx2 expression and 
inhibits Nkx2.1 in these cells, and in this way leads to the acquisition 
of a CGE fate and calretinin interneuron differentiation.
The main growth factor identified so far in determining corti-
cal interneuron fate is Shh. Shh signalling is required for specifying 
MGE identity and for the formation of somatostatin and parval-
bulim interneurons, and loss of Shh signalling leads to increased 
calretinin interneuron development in vivo43. However, although 
the CGE develops independently of Shh44, during ESC differen-
tiation the inhibition of Shh generates glutamatergic neurons and 
never gives rise to Gsx2 progenitors or calretinin interneurons14,28. 
Therefore in addition to inhibiting Shh signalling, Activin must be 
performing additional roles. Interestingly, the combination of both 
cyclopamine and RA also fails to increase Gsx2 expression and cal-
retinin interneuron formation in our cultures (data not shown), 
suggesting that this additional role does not involve the regulation 
of RA. The finding that treatment of Foxg1 +  telencephalic precur-
sors with Fgf15/19 can also generate calretinin interneurons45, and 
that Fgf15 has been shown to be a direct target of Activin signal-
ling in ESCs46, suggests that these factors may be directly regulated 
by Activin during the specification of cortical interneuron fate. It is 
worth adding that Activin’s roles in promoting differentiation and 
providing cell fate identity does not necessarily imply that these 
two processes are separable as the regulation of cell fate identity and 
differentiation are closely interlinked processes.
Cortical interneurons are of particular interest for cell transplan-
tation owing to their remarkable migratory capacity in postnatal 
cortex, their stereotypic differentiation after transplantation and 
Calretinin cortical interneurons
CGE (Gsx2+/Er81+)
Aldh1a1
Cyp26b1Gli3
ESC Telencephalic precursor
(Foxg1+)
MGE
(Nkx2.1+/Lhx6+)
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Figure 8 | Model for how Activin induces the differentiation and CGE fate in telencephalic neuronal precursors. our work suggests that during the 
neuronal differentiation of neural precursors Activin has three roles. First Activin inhibits shh signalling in a Gli3-dependent manner. second, Activin 
enhances the response of telencephalic neural precursors to RA by increasing the expression of genes that promote RA signalling, such as Aldh1a1-3, and 
by repression of those that inhibit it, such as Cyp26b1. We suggest that these changes result in a sensitization of these precursors to VitA, so that when 
these cells are presented with VitA they can rapidly undergo differentiation. The third role of Activin during the neuronal process is to promote a calretinin 
interneuron identity in the differentiating neural precursors.
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their regulation of cortical activity10–13. They are also involved in a 
number of neuropsychiatric illnesses, including epilepsy, autism and 
schizophrenia11,47. Specifically, it has been suggested that calretinin 
interneurons may be implicated in epilepsy11,48. The protocol that 
we describe in this manuscript represents a method to obtain an 
enriched source of calretinin interneurons from both mouse and 
human ESCs. Therefore, our work significantly contributes to the 
aim of generating the diverse neuronal subtypes required for the 
safe and successful use of ESCs in regenerative medicine.
Methods
Cell culture. Four mouse ESC lines were used: control E14, Sox1–GFP (46C) 
and  + / +  (that are Gli3 + / +  and therefore a wild-type line derived from the same 
genetic background as the Gli3 − / −  ESCs) and a Gli3-defective line (Xt7). All 
ESCs were maintained under standard conditions and differentiated as previously 
described15 with minor modifications. ESC lines were maintained in 0.1% gelatin-
coated flasks with GMEM supplemented with 10% FCS, NEAA, l-Glutamine, 
Sodium Pyruvate, β-mercaptoethanol (all from Gibco) and LIF (Millipore) and 
divided 1:8 or 1:10 every 2–3 days. For monolayer neural differentiation, cells were 
replated at low density (7,500 cells cm − 2) in NB (neurobasal media, Gibco) supple-
mented with B27 diluted 1:50 (Gibco), l-Glutamine and β-mercaptoethanol. Media 
was changed every day and at day 5 of differentiation, cells were split 1:3, replated 
into Poly-d-lysine/laminin-coated dishes, and maintained in NB media (control 
cells) or in NB media supplemented with 10 ng ml − 1 of Activin (R&D Systems). For 
the differentiation without RA, N2 was added to the media and cells were main-
tained on gelatin for 7 days instead of 5, then replated as normally and cultured in 
the media described. For the RA receptor inhibition, AGN193109 (Santa Cruz) and 
UVI 3003 (Tocris Bioscience) were used at 10 µm. Cyclopamine (Sigma) was used 
at 10 µm, Shh (R&D Systems) at 25 ng ml − 1 and BDNF (Sigma) at 10 ng ml − 1.
Human ESCs H1 and H7 as well as the human IPSC lines 2F8 and 4FHuang 
were maintained and differentiated as previously described39 with minor modifica-
tions. Human cells were maintained on a feeder layer of Mitomycin C-treated 
mouse embryonic fibroblasts and passaged weekly by EDTA dissociation. Cells 
were maintained in KO–DMEM with 15% KO serum replacement (both from  
Invitrogen) supplemented with 8 ng ml +  of bFGF (Preprotech), NEAA, NaPyr, 
B-ME and l-glutamine. For neural differentiation, human cells were preplated on 
gelatin-coated dishes for 60 min to remove contaminating feeder cells and then 
plated into growth-factor-reduced matrigel-coated plates (BD Biosciences). The 
basal media used for differentiation was N2B27 with both supplements at a dilution 
of 1 in 200 (Invitrogen). Neural induction was achieved with 100 ng ml − 1 noggin 
(R&D Systems), 10 µm SB431542 (Sigma) and 200 nM dorsomorphin (Tocris 
Bioscience). SB431542 was removed from the N2B27 after day 5 and noggin and 
dorsomorphin were removed after day 9 of differentiation. Pro-neural cells were 
passaged at day 11 of differentiation using 0.02% EDTA (Sigma) and manual disag-
gregation. The cells were maintained for a further 9 days before being passaged for 
a second time. The precursor cells were then plated into fibronectin-coated dishes 
and cultured with Activin at a concentration of 10 ng ml − 1 (R&D Systems).
Immunostaining. ESCs were fixed with 4% paraformaldehyde for 20 min, and 
for nuclear antigen detection an additional methanol fixation was used (20 min 
at  − 20oC). Cells were then blocked and permeabilized with 8% BSA + 0.2% Tween-
20 for 20 min at room temperature, and washed with PBS. Antibodies used were 
anti-β-III-tubulin rabbit polyclonal 1:300 (Abcam), anti-Nestin mouse monoclonal 
1:300 (BD transduction), anti-Calretinin rabbit polyclonal 1:400 (Swant) and 
anti-GABA rabbit polyclonal 1:500 (Sigma), anti-Gsx2 rabbit polyclonal (kindly 
provided by K. Campbell), anti-Foxg1 rabbit polyclonal 1:400 (Abcam), anti-Dlx2 
rabbit polyclonal 1:300 (Millipore), anti-CoupTFII mouse monoclonal 1:300 (R&D  
Systems), anti-GAD67 mouse monoclonal 1:100 (Millipore) and anti-Reelin  
mouse monoclonal 1:200 (MBL). Secondary antibodies were Alexa fluor 488 or 
568 Donkey anti-rabbit and Donkey anti-mouse (Invitrogen). For Human ESCs, 
primary antibodies used were Rabbit Tuj1 1:1,000 (Covance), mouse Nestin 1:300  
(Neuromics) and rabbit Calretinin 1:400 (Swant), incubated all night at 4 °C in  
3% serum. All data were collected from a minimum of three independent  
differentiation experiments.
RNA isolation and RT–PCR. Total RNA was extracted using RNeasy (Qiagen). 
Complementary DNA was synthesized using SuperScript III Reverse Transcriptase 
(Invitrogen), Random Nonamers (Sigma) and RNAse out (Roche). qPCR was 
performed with SYBR PCR Master Mix (Qiagen). Standard curves and melting 
curves were measured for each set of primers to confirm that only one amplicon 
was generated and β-actin was used as a house keeping gene. The expression levels 
of mRNA were calculated using the comparative CT method. Primers used are 
listed in Supplementary Table S1.
Western blotting. Cell pellets were resuspended in RIPA buffer and sonicated. 
Proteins (25–40 µg) were resolved by a 6–12% SDS–PAGE gel and subjected to 
western blot analysis. Primary antibodies used were anti-Gli1 rabbit polyclonal 
(Cell Signalling) and anti-Cyclin D1 rabbit polyclonal (Santa Cruz).
Electrophysiology. Activin-treated and control cells at day 5 were mounted  
on a recording chamber and bathed with physiological extracellular recording 
solution (composition in mM, NaCl 147, KCl 3.5, HEPES 10, Glucose 11, MgCl2 
2, CaCl2 2, pH = 7.4) at room temperature (20–22 °C). Recording sessions from 
each coverslip were limited to 75 min to ensure maximum membrane integrity and 
cell viability. Cells were visualized under an upright microscope (Olympus BXWI 
51, Japan) equipped with a ×40 objective, an infared filter, differential interference 
contrast optics and a cathode-cooled diode (CCD) video camera (Hamamatsu 
Photonics, Germany). Whole-cell current-clamp recordings were performed with 
an Axopatch 200A amplifier (Axon Instruments, USA) using glass microelectrodes 
(3–6 MΩ in resistance) filled with an internal solution containing (in mM) 140 
K-gluconate, 5 NaCl, 1 MgCl2, 10 HEPES, 1 EGTA, 2 MgATP, 0.5 LiGTP, pH 7.3, 
osmolarity 280–290 mosmol l − 1. Cells were recorded in current-clamp conditions 
for a minimum of 1–2 min after breaking into the whole-cell mode to establish 
their ability to fire APs by delivering depolarizing pulses (10–500 pA, 0.5–2 s  
duration at around 0.01 Hz).
Transplantation in the adult mouse cortex and 2-photon/confocal imaging. 
Mice (n = 2 males, >5-month-old) were given an intraperitoneal injection of an  
anaesthetic mixture (0.13 mg ketamine/0.01 mg xylazine/g body weight) and a 
small dose of dexamethasone (i.m., 0.02 ml at 4 mg ml − 1) and bupivacaine (s.c., 
0.125% in saline) immediately before the surgery and transferred to a stereotaxic 
apparatus (Stoelting). GFP-expressing cells (100,000 cells µl − 1) were injected 
through a small craniotomy (4 mm in diameter) over the somatosensory cortex49 
using glass pipettes (tip diameter ~10 µm) filled with 0.5 µl of cell solution. About 
10–100 nl volumes were injected using a picospritzer (III, General Valve) and  
several pressure pulses (20 psi; 15 ms). After a period of 1 month, mice were  
perfused and brains removed and processed for immunohistochemistry.
Immunohistochemistry and 2-photon/confocal imaging. Paraformaldehyde-
fixed brains were embedded in agarose gel and serial sections cut with a vibrating 
microtome (Leica). The sections were washed (3×10 min) in permeabilization 
buffer (0.2% TX100 in PBS) before incubation (>1 h) in blocking buffer (10% 
NGS and 0.2% TX100 in PBS). Sections were then incubated (overnight at 4 °C) 
with primary antibodies (rabbit anti-calretinin, 1:500 (Swant)) diluted in blocking 
buffer. Sections were washed (3×30 min) in PBS  +  0.2% TX100 before incubation 
(>2 h) with secondary antibody (Cy3 conjugated goat anti-rabbit, 1:500). After 
further washes (3×10 min) in PBS  +  0.2% TX100, sections were mounted on  
glass slides with Vectashield (containing 4′,6-diamidino-2-phenylindole) and  
glass coverslips.
Images were obtained using confocal (SP5II, Leica) and 2-Photon (Prairie 
Technologies) microscopy. 
References
1. Fuccillo, M., Joyner, A. L. & Fishell, G. Morphogen to mitogen: the multiple 
roles of hedgehog signalling in vertebrate neural development. Nat. Rev. 
Neurosci. 7, 772–783 (2006).
2. Maden, M. Retinoic acid in the development, regeneration and maintenance  
of the nervous system. Nat. Rev. Neurosci. 8, 755–765 (2007).
3. Siegenthaler, J. A. et al. Retinoic acid from the meninges regulates cortical 
neuron generation. Cell 139, 597–609 (2009).
4. Wang, X. J., Tegner, J., Constantinidis, C. & Goldman-Rakic, P. S. Division of 
labor among distinct subtypes of inhibitory neurons in a cortical microcircuit 
of working memory. Proc. Natl Acad. Sci. USA 101, 1368–1373 (2004).
5. Owens, D. F. & Kriegstein, A. R. Is there more to GABA than synaptic 
inhibition? Nat. Rev. Neurosci. 3, 715–727 (2002).
6. Hensch, T. K. & Stryker, M. P. Columnar architecture sculpted by GABA 
circuits in developing cat visual cortex. Science 303, 1678–1681 (2004).
7. Wonders, C. P. & Anderson, S. A. The origin and specification of cortical 
interneurons. Nat. Rev. Neurosci. 7, 687–696 (2006).
8. Sousa, V. H. & Fishell, G. Sonic hedgehog functions through dynamic changes 
in temporal competence in the developing forebrain. Curr. Opin. Genet. Dev. 
20, 391–399 (2010).
9. Miyoshi, G. et al. Genetic fate mapping reveals that the caudal ganglionic 
eminence produces a large and diverse population of superficial cortical 
interneurons. J. Neurosci. 30, 1582–1594 (2010).
10. Alvarez-Dolado, M. et al. Cortical inhibition modified by embryonic neural 
precursors grafted into the postnatal brain. J. Neurosci. 26, 7380–7389 (2006).
11. Cobos, I. et al. Mice lacking Dlx1 show subtype-specific loss of interneurons, 
reduced inhibition and epilepsy. Nat. Neurosci. 8, 1059–1068 (2005).
12. Maroof, A. M., Brown, K., Shi, S. H., Studer, L. & Anderson, S. A. Prospective 
isolation of cortical interneuron precursors from mouse embryonic stem cells. 
J. Neurosci. 30, 4667–4675 (2010).
13. Martinez-Cerdeno, V. et al. Embryonic MGE precursor cells grafted into adult 
rat striatum integrate and ameliorate motor symptoms in 6-OHDA-lesioned 
rats. Cell Stem Cell 6, 238–250 (2010).
14. Gaspard, N. et al. An intrinsic mechanism of corticogenesis from embryonic 
stem cells. Nature 455, 351–357 (2008).
ARTICLE 

nATuRE CommunICATIons | DoI: 10.1038/ncomms1817
nATuRE CommunICATIons | 3:841 | DoI: 10.1038/ncomms1817 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
15. Ying, Q. L., Stavridis, M., Griffiths, D., Li, M. & Smith, A. Conversion 
of embryonic stem cells into neuroectodermal precursors in adherent 
monoculture. Nat. Biotechnol. 21, 183–186 (2003).
16. Feijen, A., Goumans, M. J. & van den Eijnden-van Raaij, A. J. Expression of 
activin subunits, activin receptors and follistatin in postimplantation mouse 
embryos suggests specific developmental functions for different activins. 
Development 120, 3621–3637 (1994).
17. Maira, M., Long, J. E., Lee, A. Y., Rubenstein, J. L. & Stifani, S. Role for TGF-
beta superfamily signaling in telencephalic GABAergic neuron development.  
J. Neurodev. Disord. 2, 48–60 (2010).
18. Elkabetz, Y. et al. Human ES cell-derived neural rosettes reveal a  
functionally distinct early neural stem cell stage. Genes Dev. 22, 152–165 
(2008).
19. Kenney, A. M. & Rowitch, D. H. Sonic hedgehog promotes G(1) cyclin 
expression and sustained cell cycle progression in mammalian neuronal 
precursors. Mol. Cell. Biol. 20, 9055–9067 (2000).
20. Liu, F., Massague, J. & Ruiz i Altaba, A. Carboxy-terminally truncated Gli3 
proteins associate with Smads. Nat. Genet. 20, 325–326 (1998).
21. Quinn, J. C., Molinek, M., Mason, J. O. & Price, D. J. Gli3 is required 
autonomously for dorsal telencephalic cells to adopt appropriate fates during 
embryonic forebrain development. Dev. Biol. 327, 204–215 (2009).
22. Silvestri, C. et al. Genome-wide identification of Smad/Foxh1 targets reveals a 
role for Foxh1 in retinoic acid regulation and forebrain development. Dev. Cell. 
14, 411–423 (2008).
23. Gulacsi, A. & Anderson, S. A. Shh maintains Nkx2.1 in the MGE by a Gli3-
independent mechanism. Cereb. Cortex 16 (Suppl 1), i89–95 (2006).
24. Sussel, L., Marin, O., Kimura, S. & Rubenstein, J. L. Loss of Nkx2.1 homeobox 
gene function results in a ventral to dorsal molecular respecification within  
the basal telencephalon: evidence for a transformation of the pallidum into  
the striatum. Development 126, 3359–3370 (1999).
25. Xu, Q., Tam, M. & Anderson, S. A. Fate mapping Nkx2.1-lineage cells in the 
mouse telencephalon. J. Comp. Neurol. 506, 16–29 (2008).
26. Grigoriou, M., Tucker, A. S., Sharpe, P. T. & Pachnis, V. Expression and 
regulation of Lhx6 and Lhx7, a novel subfamily of LIM homeodomain 
encoding genes, suggests a role in mammalian head development. Development 
125, 2063–2074 (1998).
27. Xu, Q., Cobos, I., De La Cruz, E., Rubenstein, J. L. & Anderson, S. A. Origins of 
cortical interneuron subtypes. J. Neurosci. 24, 2612–2622 (2004).
28. Watanabe, K. et al. Directed differentiation of telencephalic precursors from 
embryonic stem cells. Nat. Neurosci. 8, 288–296 (2005).
29. Flames, N. et al. Delineation of multiple subpallial progenitor domains by the 
combinatorial expression of transcriptional codes. J. Neurosci. 27, 9682–9695 
(2007).
30. Waclaw, R. R. & Campbell, K. Regional control of cortical lamination.  
Nat. Neurosci. 12, 1211–1212 (2009).
31. Willi-Monnerat, S. et al. Comprehensive spatiotemporal transcriptomic 
analyses of the ganglionic eminences demonstrate the uniqueness of its caudal 
subdivision. Mol. Cell. Neurosci. 37, 845–856 (2008).
32. Kanatani, S., Yozu, M., Tabata, H. & Nakajima, K. COUP-TFII is preferentially 
expressed in the caudal ganglionic eminence and is involved in the caudal 
migratory stream. J. Neurosci. 28, 13582–13591 (2008).
33. Long, J. E., Cobos, I., Potter, G. B. & Rubenstein, J. L. Dlx1&2 and Mash1 
transcription factors control MGE and CGE patterning and differentiation 
through parallel and overlapping pathways. Cereb. Cortex 19(Suppl 1), i96–106 
(2009).
34. Nery, S., Fishell, G. & Corbin, J. G. The caudal ganglionic eminence is a 
source of distinct cortical and subcortical cell populations. Nat. Neurosci. 5, 
1279–1287 (2002).
35. Marin, O. & Rubenstein, J. L. Cell migration in the forebrain. Annu. Rev. 
Neurosci. 26, 441–483 (2003).
36. Waclaw, R. R., Wang, B., Pei, Z., Ehrman, L. A. & Campbell, K. Distinct 
temporal requirements for the homeobox gene Gsx2 in specifying striatal and 
olfactory bulb neuronal fates. Neuron 63, 451–465 (2009).
37. Anderson, S. A., Eisenstat, D. D., Shi, L. & Rubenstein, J. L. Interneuron 
migration from basal forebrain to neocortex: dependence on Dlx genes. Science 
278, 474–476 (1997).
38. Liu, J. K., Ghattas, I., Liu, S., Chen, S. & Rubenstein, J. L. Dlx genes encode 
DNA-binding proteins that are expressed in an overlapping and sequential 
pattern during basal ganglia differentiation. Dev. Dyn. 210, 498–512 (1997).
39. Chambers, S. M. et al. Highly efficient neural conversion of human ES and 
iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27, 275–280 
(2009).
40. Patani, R. et al. Retinoid-independent motor neurogenesis from human 
embryonic stem cells reveals a medial columnar ground state. Nat. Commun.  
2, 214 (2011).
41. Timmer, J., Chesnutt, C. & Niswander, L. The activin signaling pathway 
promotes differentiation of dI3 interneurons in the spinal neural tube.  
Dev. Biol. 285, 1–10 (2005).
42. Garcia-Campmany, L. & Marti, E. The TGF beta intracellular effector Smad3 
regulates neuronal differentiation and cell fate specification in the developing 
spinal cord. Development 134, 65–75 (2007).
43. Xu, Q. et al. Sonic hedgehog signaling confers ventral telencephalic progenitors 
with distinct cortical interneuron fates. Neuron 65, 328–340 (2010).
44. Machold, R. et al. Sonic hedgehog is required for progenitor cell maintenance 
in telencephalic stem cell niches. Neuron 39, 937–950 (2003).
45. Danjo, T. et al. Subregional specification of embryonic stem cell-derived ventral 
telencephalic tissues by timed and combinatory treatment with extrinsic 
signals. J. Neurosci. 31, 1919–1933 (2011).
46. Guzman-Ayala, M. et al. Graded Smad2/3 activation is converted directly into 
levels of target gene expression in embryonic stem cells. PLoS One 4, e4268 
(2009).
47. Levitt, P., Eagleson, K. L. & Powell, E. M. Regulation of neocortical interneuron 
development and the implications for neurodevelopmental disorders. Trends 
Neurosci. 27, 400–406 (2004).
48. Toth, K. et al. Loss and reorganization of calretinin-containing interneurons in 
the epileptic human hippocampus. Brain 133, 2763–2777 (2010).
49. Holtmaat, A. et al. Long-term, high-resolution imaging in the mouse neocortex 
through a chronic cranial window. Nat. Protoc. 4, 1128–1144 (2009).
Acknowledgements
We thank Jo Jackson for help with the transplantation experiments. We would specially 
like to thank Rita Lopes, James Briscoe, Domingos Henrique, Vasso Episkopou, 
Veronique Azuara and members of the Molecular Embryology group for critical 
suggestions during the course of the work. We are grateful to David Price for the Gli3 
ESCs, to Kenneth Campbell for the Gsx2 antibody, to Austin Smith for the 2F8 iPSC 
line and to Kuo Hsuan Chang for the 4FHuang iPSC line. This work was funded by the 
Lister Institute of Preventative Medicine, MRC, Royal Society, Wellcome Trust and EU 
Framework 6 program.
Author contributions
S.C., M.L. and T.A.R. designed the study. S.C. carried out and analysed the mESC 
experiments, and C.A. the hESC experiments. A.G.D. and M.A.U. performed and 
analysed the electrophysiological studies. G.L. and V.d.P. performed and analysed the 
injections of ESCs into adult mouse brains. S.C., M.L. and T.A.R. wrote the paper.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing financial interests: The authors declare no competing financial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Cambray, S. et al. Activin induces cortical interneuron identity 
and differentiation in embryonic stem cell-derived telencephalic neural precursors.  
Nat. Commun. 3:841 doi: 10.1038/ncomms1817 (2012).
License: This work is licensed under a Creative Commons Attribution-NonCommercial-
Share Alike 3.0 Unported License. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-sa/3.0/
